MBAI (Check-Cap) 5-Year EBITDA Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBAI Check-Cap Ltd MBAI
21 GF Score
Price $6.58
! 2 Warning Signs
View Full Analysis

What is Check-Cap 5-Year EBITDA Growth Rate?

Check-Cap MBAI -0.60% 21 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates MBAI with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Check-Cap's EBITDA per Share for the six months ended in Dec. 2025 was $5.98.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Check-Cap was 59.80% per year. The lowest was -133.80% per year. And the median was 33.90% per year.

Check-Cap  (NAS:MBAI) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Check-Cap 5-Year EBITDA Growth Rate Related Terms

MBAI vs XWEL, NDRA, BIAF: 5-Year EBITDA Growth Rate Comparison

For the Diagnostics & Research subindustry, Check-Cap's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Check-Cap 5-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Check-Cap's 5-Year EBITDA Growth Rate falls into.


MBAI
21GF Score
Check-Cap Ltd MBAI
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Check-Cap 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Check-Cap (MBAI) has a 5-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Check-Cap and its competitors.
Is Check-Cap's 5-Year EBITDA Growth Rate too high?
Check-Cap's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Check-Cap has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's 5-Year EBITDA Growth Rate compare to XWEL and NDRA?
Check-Cap's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
A good 5-Year EBITDA Growth Rate depends on the Medical Diagnostics & Research industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Check-Cap and its competitors. Check-Cap's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (MBAI) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Check-Cap's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Check-Cap (MBAI), the current 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Check-Cap Business Description

Other Exchanges 7CC:Germany
Address 29 Abba Hushi Avenue, P.O. Box 1271, Mount Carmel, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
21GF Score

Get the complete analysis for MBAI

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.58
Price